Is it finally time to invest in Woodford Patient Capital Trust plc?

Why I’ve come out surprisingly (for me) bullish on the prospects for Woodford patient Capital Trust plc (LON: WPCT).

 

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

At 75p or so, the share price of Woodford Patient Capital Trust (LSE: WPCT) is where it was when I last wrote about the closed-ended investment fund in February. There’s been a bit of wiggling up and down, but there is evidence of basing on the chart following the plunge of around 30% since last summer. Is this a buying opportunity?

Declining net asset value

In February, the trust reported its net asset value at 91.22p per share. More recently, the figure is 82.59p per share, so with the share price near the same level, value has declined rather than increased. The fundamentals don’t support the basing action I’m seeing on the chart. Maybe the stock is in for further falls, especially if more of the underlying investments disappoint.

Neil Woodford’s public foray into the world of speculative stocks started in 2015 with the launch of FTSE 250 index-listed Woodford Patient Capital Trust, but things haven’t been going well. Last month, for example, one of the biggest holdings, Nasdaq-listed Irish biotech company Prothena, saw its stock tumbling when its most advanced treatment, Pronto, failed a trial. Prothena immediately stopped all spending on the drug that was aimed at treating AL amyloidosis.

Another example is the trust’s now-smallest holding, London-listed Midatech Pharma, an early-stage biopharmaceutical company that focuses on commercialising and developing products in oncology and other therapeutic areas. I can sum up the story of that one so far by telling you that it listed on the stock market in January 2015 with its share price close to 265p, a far cry from today’s level around 29p.

Potential billion-dollar companies?

However, Neil Woodford is reported as saying, in the teeth of such disappointments, that the trust has stakes in several companies that could be worth billions of dollars each in the next five years. On the basis of that potential, and assuming that the trust sticks with its original investments without taking any more punts on jam-tomorrow stocks, I think the lower share price makes it more attractive.

Now we are three years on from when the original investments were made, the probabilities are playing out. Losers such as Midatech become less of a problem. Already the stock has dropped to be the smallest holding in the trust – almost an insignificant weighting – and losers can only lose the trust 100% of its investment. Winners, on the other hand, are uncapped and may go on to deliver percentage returns in the thousands. Today’s losers could go also go on to win in the end.

With the benefit of hindsight, it’s easy to criticise the trust’s apparent initial scattergun approach to speculating on profitless companies.  Successful stock trader Mark Minervini advocates waiting for evidence of success in the financial figures of early-stage companies before investing, arguing that investment returns can still be spectacular with reduced exposure to firms that go on to fail — more like using a rifle than a shotgun. However, with the risks and potential now playing out in the fund’s holdings, ‘right now’ could indeed be a good time to look closely at Woodford Patient Capital Trust.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

This FTSE 250 stock has a stunning 10.8% yield! Time to consider buying?

Harvey Jones is dazzled by the amount of income on offer from this FTSE 250 stock, but not too dazzled…

Read more »

Young female hand showing five fingers.
Investing Articles

£10,000 invested in these 5 FTSE 100 shares in June 2020 would now be worth…

Our writer considers the best-performing shares on the FTSE 100 since the summer of 2020, and takes a closer look…

Read more »

Illustration of flames over a black background
Investing Articles

Just released: June’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

Trader on video call from his home office
Investing Articles

A 7.3% yield but down 22% from September, is it time for me to buy more of an overlooked FTSE gem?

This FTSE 100 commodities giant has been hit by concerns over Chinese growth and US tariffs. But are both overdone,…

Read more »

Middle-aged black male working at home desk
Investing Articles

Where’s the Lloyds share price heading in 2025? Here’s what the experts say

With the Lloyds share price already posting strong gains in 2025, Mark Hartley explores where it could go next --…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Down 8% from its one-year high, is Unilever’s share price too cheap for me to pass up?

Heavyweight FTSE 100 conglomerate Unilever has seen its share price slide 8% in recent months. But does this mean it's…

Read more »

Tariffs and Global Economic Supply Chains
US Stock

Is it worth me buying S&P 500 stocks with the index close to record highs?

Jon Smith explains why he's more focused on active stock picking when it comes to the S&P 500 index right…

Read more »

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing Articles

Warren Buffett’s stock is getting cheaper! Is this an opportunity for investors?

Shares of Warren Buffett’s Berkshire Hathaway have fallen in value since the legendary investor announced his retirement plans.

Read more »